Tick-borne encephalitis virus-neutralizing antibodies in different immunoglobulin preparations

Clinical and Vaccine Immunology

Volumn 19, Issue 4, 2012, Pages 623-625

  Rabel, Philip O ^a   Planitzer, Christina B ^a   Farcet, Maria R ^a   Kreil, Thomas R ^a  

^a BAXTER BIOSCIENCE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; NEUTRALIZING ANTIBODY;

ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNE RESPONSE; INFECTION PREVENTION; INTERMETHOD COMPARISON; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; SEROPREVALENCE; TICK BORNE ENCEPHALITIS; TICK BORNE ENCEPHALITIS FLAVIVIRUS; VACCINATION; VACCINE PRODUCTION; VIRUS NEUTRALIZATION; VIRUS STRAIN;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ENCEPHALITIS VIRUSES, TICK-BORNE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES;

EID: 84859297803     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05705-11     Document Type: Article

References (39)

1. Audet S, et al. 2006. Measles-virus-neutralizing antibodies in intravenous immunoglobulins. J. Infect. Dis. 194:781-789. (Pubitemid 44344125)
2. Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. 2003. Intravenous immunoglobulin for infectious diseases: tailor-made or universal? J. Infect. Dis. 188:1610-1611. (Pubitemid 37523949)
3. Beck OE. 1981. Distribution of virus antibody activity among human IgG subclasses. Clin. Exp. Immunol. 43:626-632. (Pubitemid 11130429)
4. Ben-Nathan D, et al. 2009. Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection. BMC Infect. Dis. 9:18.
5. Centers for Disease Control and Prevention. 2010. Tick-borne encephalitis among U.S. travelers to Europe and Asia - 2000-2009. MMWR Morb. Mortal. Wkly. Rep. 59:335-338.
6. Charrel RN, et al. 2004. Tick-borne virus diseases of human interest in Europe. Clin. Microbiol. Infect. 10:1040-1055. (Pubitemid 40044976)
7. Donoso MO, Escadafal C, Niedrig M, Pfeffer M, on behalf of the Working Group For Tick-Borne Encephalitis Virus. 2011. Tick-borne encephalitis in Europe, 2007 to 2009. Euro Surveill. 16(39):pii=19976.
8. Farcet MR, Planitzer CB, Stein O, Modrof J, Kreil TR. 2010. Hepatitis A virus antibodies in immunoglobulin preparations. J. Allergy Clin. Immunol. 125:198-202.
9. Fritz R, et al. 2012. Quantitative comparison of the cross-protection induced by tick-borne encephalitis virus vaccines based on European and Far Eastern virus subtypes. Vaccine 30(6):1165-1169.
10. GAO. 1998. Blood plasma safety - plasma product risks are low if good manufacturing practices are followed - report to the Chairman, Subcommittee on Human Resources, Committee on Government Reform and Oversight, House of Representatives. http://www.gao.gov/assets/230/226266.pdf.
11. Gilljam G, Wahren B. 1989. Properties of IgG subclasses to human cytomegalovirus. J. Virol. Methods 25:139-151.
12. Gritsun TS, Lashkevich VA, Gould EA. 2003. Tick-borne encephalitis. Antiviral Res. 57:129-146. (Pubitemid 36254727)
13. Heinz FX, Holzmann H, Essl A, Kundi M. 2007. Field effectiveness of vaccination against tick-borne encephalitis. Vaccine 25:7559-7567.
14. Hofmeister Y, et al. 2011. Human IgG subclasses: in vitro neutralization of and in vivo protection against West Nile virus. J. Virol. 85:1896-1899.
15. Holzmann H, et al. 1992. Molecular epidemiology of tick-borne encephalitis virus: cross-protection between European and Far Eastern subtypes. Vaccine 10:345-349.
16. Klockmann U, et al. 1991. Humoral immunity against tick-borne encephalitis virus following manifest disease and active immunization. Vaccine 9:42-46.
17. Kreil TR, Burger I, Attakpah E, Olas K, Eibl MM. 1998. Passive immunization reduces immunity that results from simultaneous active immunization against tick-borne encephalitis virus in a mouse model. Vaccine 16:955-959. (Pubitemid 28276007)
18. Lejtenyi D, Mazer B. 2008. Consistency of protective antibody levels across lots of intravenous immunoglobulin preparations. J. Allergy Clin. Immunol. 121:254-255.
19. Leonova GN, Pavlenko EV. 2009. Characterization of neutralizing antibodies to Far Eastern of tick-borne encephalitis virus subtype and the antibody avidity for four tick-borne encephalitis vaccines in human. Vaccine 27:2899-2904.
20. Mansfield KL, et al. 2009. Tick-borne encephalitis virus - a review of an emerging zoonosis. J. Gen. Virol. 90:1781-1794.
21. Matejtschuk P, Chidwick K, Prince A, More JE, Goldblatt D. 2002. A direct comparison of the antigen-specific antibody profiles of intravenous immunoglobulins derived from US and UK donor plasma. Vox Sang. 83:17-22. (Pubitemid 36806494)
22. Orange JS, et al. 2006. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J. Allergy Clin. Immunol. 117:S525-S553.
23. Orlinger KK, et al. 2011. A tick-borne encephalitis virus vaccine based on the European prototype strain induces broadly reactive cross-neutralizing antibodies in humans. J. Infect. Dis. 203:1556-1564.
24. Planitzer CB, Farcet MR, Schiff RI, Ochs HD, Kreil TR. 2011. Neutralization of different echovirus serotypes by individual lots of intravenous immunoglobulin. J. Med. Virol. 83:305-310.
25. Planitzer CB, Modrof J, Kreil TR. 2007. West Nile virus neutralization by US plasma-derived immunoglobulin products. J. Infect. Dis. 196:435-440. (Pubitemid 47093894)
26. Planitzer CB, Modrof J, Yu MY, Kreil TR. 2009. West Nile virus infection in plasma of blood and plasma donors, United States. Emerg. Infect. Dis. 15:1668-1670.
27. Planitzer CB, Saemann MD, Gajek H, Farcet MR, Kreil TR. 2011. Cytomegalovirus neutralization by hyperimmune and standard intravenous immunoglobulin preparations. Transplantation 92:267-270.
28. ProMED-mail. 31 July 2009, posting date. Tick-borne encephalitis - Russia (06): Chelyabinsk. Archive number 20090731.2691. http://www .promedmail.org/direct.php?id=20090731.2691.
29. ProMED-mail. 24 May 2009, posting date. Tick-borne encephalitis - Russia (03): Yaroslavl. Archive number 20090524.1944. http://www.promedmail.org/direct. php?id=20090524.1944.
30. ProMED-mail. 21 July 2007, posting date. Tick-borne encephalitis - Russia: Irkutsk, Arkhangelsk, Kemerovo. Archive number 20070721.2333. http://www.promedmail.org/direct.php?id=20070721.2333.
31. Rabel P, et al. 2011. Increasing West Nile virus antibody titres in central European plasma donors from 2006 to 2010. Euro Surveill. 16(10): pii=19812.
32. Rodrigo WW, et al. 2009. Dengue virus neutralization is modulated by IgG antibody subclass and Fcγ receptor subtype. Virology 394:175-182.
33. Ruzek D, Dobler G, Mantke OD. 2010. Tick-borne encephalitis: pathogenesis and clinical implications. Travel Med. Infect. Dis. 8:223-232.
34. Seidel MG, Grohmann E, Sadeghi K, Heitger A, Forster-Waldl E. 2010. Vaccination against tick-borne encephalitis virus tests specific IgG production ability in patients under immunoglobulin substitution therapy. Vaccine 28:6621-6626.
35. Suess J. 2011. Tick-borne encephalitis 2010: epidemiology, risk areas, and virus strains in Europe and Asia - an overview. Ticks Tick Borne Dis. 2:2-15.
36. Suess J. 2008. Tick-borne encephalitis in Europe and beyond - the epidemiological situation as of 2007. Euro Surveill. 13(26):pii=18916.
37. Teschner W, Poelsler G, Butterweck HA, Mais-Paul U, Kreil TR. 2010. Manufacturing of IVIG, p 13-42. In Lazarus AH, Semple JW (ed), Immunoglobulin therapy. AABB Press, Bethesda, MD.
38. von Hedenstrom M, Heberle U, Theobald K. 1995. Vaccination against tick-borne encephalitis (TBE): influence of simultaneous application of TBE immunoglobulin on seroconversion and rate of adverse events. Vaccine 13:759 -762.
39. Wiedermann U. 2010. Tick borne encephalitis TBE - vaccination in nonendemic countries. Travel Med. Infect. Dis. 8:251-256.